FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

99 letters match. Newest first.

  1. Woodbine Products Company Inc.

    Inspection found Woodbine Products, an Ohio OTC drug maker, failed to test incoming ingredients like glycerin and propylene glycol for identity.

    High risk
  2. Spa De Soleil, Inc.

    FDA cites Spa De Soleil for CGMP violations in OTC topical drugs, including water system failures and missing component identity testing.

    High risk
  3. Sklar Personal Care Inc.

    Sklar Personal Care’s drug facility failed CGMP (current good manufacturing practice), including untested raw materials and inadequate cleaning, process validation, and quality oversight.

    High risk
  4. CDL Services, Inc. DBA Technichem

    FDA warned CDL Services (Technichem), an Anaheim OTC drug maker, that it released hand sanitizer and hand soap batches without testing.

    High risk
  5. DeVere Manufacturing Inc.

    FDA warned DeVere Manufacturing in Janesville, Wisconsin, that its OTC hand sanitizers are adulterated after a June 2025 inspection found CGMP failures.

    High risk
  6. World Perfumes Inc.

    World Perfumes failed to test drug ingredients for toxic contaminants and had inadequate water, FDA says.

    High risk
  7. DermaRite Industries, LLC

    DermaRite failed CGMP and sold unapproved, misbranded OTC topical drugs, FDA says.

    High risk
  8. RNA Bio/Pharma, Incorporated

    FDA found RNA Bio/Pharma failed to test homeopathic oral liquid drugs for dangerous contaminants and did not validate its water system.

    High risk
  9. Naturich Cosmetique Labs

    FDA warned Naturich Cosmetique Labs over inadequate manufacturing controls for over-the-counter topical drugs, including contaminated water and untested ingredients.

    High risk
  10. Kabana Skin Care LLC

    Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.

    High risk
  11. Medical Chemical Corporation

    FDA warned Medical Chemical Corp over manufacturing violations, unapproved Tincture Green Soap, and improper drug listing.

    High risk
  12. Nature’s Fusions LLC

    FDA cited Nature's Fusions for over-the-counter hand sanitizer manufacturing with inadequate stability, component and finished-product testing, and water controls.

    High risk
  13. Ningbo Riway Industrial Co., Ltd.

    Ningbo Riway Industrial, an OTC drug maker in China, was cited for manufacturing-practice failures and unapproved antiseptic wipes.

    High risk
  14. Dyno Manufacturing, Inc.

    Dyno Manufacturing’s OTC hand sanitizer and antibacterial soap drugs lacked raw-material identity testing and other required manufacturing controls.

    High risk
  15. Rite-Kem Incorporated

    FDA warned Rite-Kem over inadequate current good manufacturing practice testing of over-the-counter drugs, including hand sanitizers and antimicrobial products.

    High risk
  16. Linghai ZhanWang Biotechnology Co., Ltd

    Linghai ZhanWang Biotechnology's OTC drugs, including antimicrobial wipes, fail manufacturing quality rules; FDA cites missing tests.

    High risk
  17. Shantou Kangjie Daily Chemical Industry Co., Ltd

    FDA warns Shantou Kangjie over CGMP failures for OTC drugs, including untested ethanol and no quality unit.

    High risk
  18. Imperial Palace Commodity -Dongguan- Co., Ltd.

    FDA warns Chinese maker of OTC alcohol wipes that weak component testing and process validation make its drugs adulterated.

    High risk
  19. Kardesler Ucan Yaglar Sanayi Anonim Sirketi

    Turkey-based OTC drug maker Kardesler Ucan failed to test glycerin, propylene glycol and ethanol for dangerous impurities and is on US import alert.

    High risk
  20. Sombra Cosmetics, Inc.

    FDA warned Sombra Cosmetics of OTC drug CGMP violations, including inadequate water controls and component testing.

    High risk
  21. Hangzhou Huiji Biotechnology Co., Ltd.

    FDA warned Hangzhou Huiji Biotechnology over CGMP failures in OTC hand sanitizers, including missing glycerin and ethanol safety tests.

    High risk
  22. Zhejiang Qimei Cosmetics Co., Ltd.

    Zhejiang Qimei Cosmetics drew an FDA warning for CGMP violations in sterile-labeled OTC isopropyl alcohol prep pads.

    High risk
  23. Little Moon Essentials, LLC

    FDA warns Little Moon Essentials over CGMP failures and unapproved topical analgesic drugs made in Dania Beach, Florida.

    High risk
  24. Diamond Chemical Co., Inc.

    Diamond Chemical Co. in East Rutherford, NJ, made OTC hand sanitizers without required ingredient and finished-product testing or process validation.

    High risk
  25. EnviroServe Chemicals & Cleaners Ltd.

    EnviroServe's SOPURE hand sanitizer had manufacturing-quality violations and was sold as an unapproved, misleadingly labeled drug.

    High risk
  26. AnuMed International, LLC

    FDA warned AnuMed International about unapproved drugs, misleading FDA claims, and manufacturing quality failures.

    High risk
  27. Nowrez & Ismail Shukri Company

    FDA warns Jordanian OTC drug maker Nowrez & Ismail Shukri over CGMP violations and import alert.

    High risk
  28. Yahon Enterprise Co., Ltd.

    FDA warned Yahon Enterprise over manufacturing quality failures for OTC antiseptic wipes after a December 2023 inspection.

    High risk
  29. Landy International

    FDA found Landy International’s OTC hand sanitizers adulterated after a 2023 inspection revealed missing testing, unsafe water, and data integrity failures.

    High risk
  30. TCT Nutraceuticals SDN. BHD

    FDA warns TCT Nutraceuticals over manufacturing-rule failures in OTC hand sanitizer, including no methanol testing.

    High risk
  31. Aruba Aloe Balm N.V.

    Aruba Aloe Balm N.V. made OTC drugs with methanol-contaminated ethanol and failed CGMP, prompting recall and import alert.

    High risk
  32. Seatex, LLC

    FDA: Seatex made hand sanitizer on equipment also used for floor cleaner and skipped ingredient identity tests.

    High risk
  33. Natuzen Co., Ltd.

    Natuzen Co., Ltd. failed drug manufacturing rules for OTC products including Atoren Hand Sanitizer, with no methanol testing, cleaning validation, or quality unit.

    High risk
  34. Seatex, LLC

    Seatex, LLC made OTC hand sanitizer drugs with inadequate current good manufacturing practice (CGMP), including shared equipment with industrial chemicals and missing component testing.

    High risk
  35. Global Cosmetics Company Limited

    FDA warns Global Cosmetics over manufacturing quality failures in OTC hand sanitizer, including no methanol testing of ethanol.

    High risk
  36. Master Paints & Chemicals Corp.

    FDA warned Master Paints & Chemicals Corp. over inadequate testing and quality oversight for OTC drugs including hand sanitizer.

    High risk
  37. Bodywell Natural Skin Care Inc.

    FDA warned Bodywell Natural Skin Care that its OTC hand sanitizer and Dermalere creams were adulterated due to CGMP failures and unapproved drug claims.

    High risk
  38. Deqing Jiarou Daily Chemical Co., Ltd.

    Deqing Jiarou failed current good manufacturing practice (CGMP) for OTC hand sanitizer, including no methanol testing of ethanol.

    High risk
  39. Higley Industries, Inc.

    FDA warns Higley Industries over CGMP failures in OTC drug manufacturing, including untested ethanol and glycerin.

    High risk
  40. Cosmetic Specialty Labs, Inc.

    FDA warned Cosmetic Specialty Labs after an inspection found manufacturing failures in OTC drugs and an unlisted product.

    High risk
  41. Nantong Furuida Packaging Products Co., Ltd.

    Nantong Furuida, an over-the-counter drug manufacturer, failed required manufacturing controls and methanol checks, leading to an FDA import alert.

    High risk
  42. Prime Lab LLC

    Prime Lab LLC failed U.S. drug manufacturing quality rules for over-the-counter hand soaps and sanitizers, including raw-material testing and shared toxic equipment.

    High risk
  43. Inopak, Ltd.

    Inopak, Ltd. was warned of CGMP (current good manufacturing practice) violations after inspection: poor quality oversight of contract-made hand sanitizer and missing stability testing.

    High risk
  44. Xiamen Wally Bath Manufacture Co., Ltd.

    FDA warns Xiamen Wally Bath over current good manufacturing practice failures for over-the-counter hand sanitizer, including raw material and release testing gaps.

    High risk
  45. Saruhan Kimya Ve Temizlik Urunleri Sanayi Ticaret Anonim Sirketi Corlu Subesi

    FDA found manufacturing violations at Turkish OTC drug maker, including missing identity, release, and stability testing for hand sanitizers.

    High risk
  46. Fuller Industries Inc.

    FDA warns Fuller Industries over current good manufacturing practice violations in OTC hand soaps and sanitizers, including quality oversight and ingredient testing.

    High risk
  47. Pharmaplast S.A.E.

    FDA cited Pharmaplast S.A.E. for failing to test drug components, including glycerin and ethanol, for dangerous contaminants.

    High risk
  48. Chemical Services Group, Inc./Royal Chemical Company

    Royal Chemical Company made OTC hand sanitizer on equipment shared with industrial chemicals, and FDA found cleaning, supplier testing and quality unit failures.

    High risk
  49. Omega Packaging Corp

    Omega Packaging Corp failed to test hand sanitizer ingredients and validate processes, FDA found.

    High risk
  50. NuGeneration Technologies LLC

    FDA inspected NuGeneration Technologies' Emeryville, California drug plant and found CGMP failures in hand sanitizer release testing, ingredient and water testing, stability and process validation.

    High risk